Sanifit Inc

Sanifit is a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for progressive vascular calcification disorders. With offices in Spain and the United States, Sanifit focuses on addressing calciphylaxis and peripheral artery disease in patients with End Stage Kidney Disease (ESKD). Their lead compound, SNF472, is a selective and potent inhibitor of hydroxyapatite crystallization, which is the final common pathway leading to vascular calcification. SNF472 has shown promising results in clinical trials, including reducing coronary artery calcium progression and improving wound healing and pain in ESKD patients.

Sanifit is dedicated to advancing the treatment options for calcification disorders and has received orphan drug designation from the FDA and EMA for the treatment of calciphylaxis. Their ongoing research and development efforts aim to provide effective therapies for patients suffering from these debilitating conditions, ultimately improving their quality of life and reducing the risk of cardiovascular diseases associated with vascular calcification.

Generated from the website